Abstract

With the increasing use of immunotherapy, there has been an associated increased survival in many cancers but has also resulted in unregulated organ-specific toxicities. In this chapter, we discuss the renal toxicities associated with a checkpoint inhibitor (CPI) from the typical acute tubulointersitial nephritis to glomerulonephritis, their proposed mechanisms, and treatments. We also discuss the use of CPI and reactivation of preexisting auto-immune diseases and focus on renal cell cancer in setting of Chronic kidney disease (CKD). Transplant rejection in the setting of CPI use is yet to be further studied, and available data is presented in this chapter.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer
Pages287-293
Number of pages7
Volume1244
DOIs
StateE-pub ahead of print - Apr 17 2020

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1244
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Acute interstitial nephritis
  • Autoimmune disease induction
  • Immune-related adverse events
  • Organ transplant rejection
  • Renal cell cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Renal Toxicity'. Together they form a unique fingerprint.

Cite this